miRNA	gene	miRNA_log2FC	miRNA_pvalue	gene_log2FC	gene_pvalue	interactions	correlation_beta	correlation_pvalue	PMID	evidence	outcome	cancer
hsa-let-7a-5p	AKT2	-1.37014061604018	3.11451492971224e-14	0.158500088541505	0.113504798741429	TargetScan	-0.119930037553526	1.13227688326527e-06		NA	NA	NA
hsa-miR-29a-3p	AKT2	0.101650412194573	0.573201097011668	0.158500088541505	0.113504798741429	MirTarget	-0.104368014677354	4.26511869332683e-05	24076586	Furthermore a feed-back loop comprising of c-Myc miR-29 family and Akt2 were found in myeloid leukemogenesis		acute myeloid leukemia
hsa-miR-106b-5p	AKT3	1.47447672652218	1.32004094930462e-13	-1.44031241124732	2.576504600149e-09	miRNATAP	-0.158920731526324	0.00425859940487133		NA	NA	NA
hsa-miR-107	AKT3	0.658676029898313	5.11480446318819e-07	-1.44031241124732	2.576504600149e-09	PITA;miRanda	-0.256548300142307	0.00309702957622585		NA	NA	NA
hsa-miR-146b-5p	AKT3	1.0922867893808	5.63754607494775e-06	-1.44031241124732	2.576504600149e-09	miRNAWalker2_validate	-0.14508398550335	0.00188822517544197		NA	NA	NA
hsa-miR-15a-5p	AKT3	1.62575353599172	1.55312121019827e-19	-1.44031241124732	2.576504600149e-09	miRNAWalker2_validate;miRTarBase;miRNATAP	-0.412918804091755	4.08840965026726e-12		NA	NA	NA
hsa-miR-16-5p	AKT3	0.749619098384047	4.11649450706988e-06	-1.44031241124732	2.576504600149e-09	miRNAWalker2_validate;miRTarBase;miRNATAP	-0.269698520974258	9.94440318719177e-05		NA	NA	NA
hsa-miR-17-5p	AKT3	2.07078488653279	2.77403038572568e-19	-1.44031241124732	2.576504600149e-09	TargetScan;miRNATAP	-0.217476886844258	3.56953935954486e-06		NA	NA	NA
hsa-miR-181a-5p	AKT3	-0.375429731222937	0.0562142867129802	-1.44031241124732	2.576504600149e-09	miRNATAP	-0.22550600060725	9.19470016250579e-05		NA	NA	NA
hsa-miR-181b-5p	AKT3	0.668793269169928	0.000239998092406404	-1.44031241124732	2.576504600149e-09	miRNATAP	-0.367498754199467	2.09865276667175e-09		NA	NA	NA
hsa-miR-20a-5p	AKT3	2.64649625616975	5.1469418982085e-27	-1.44031241124732	2.576504600149e-09	miRNATAP	-0.24430728120197	1.27608550819212e-08		NA	NA	NA
hsa-miR-22-3p	AKT3	1.42501909916631	1.72295005910055e-25	-1.44031241124732	2.576504600149e-09	miRNATAP	-0.259390140878921	0.0010937362716222		NA	NA	NA
hsa-miR-29b-2-5p	AKT3	0.345881055247341	0.194842633194187	-1.44031241124732	2.576504600149e-09	mirMAP	-0.181342398720756	1.80199534450665e-05		NA	NA	NA
hsa-miR-29b-3p	AKT3	3.10527711861309	3.01242507282711e-32	-1.44031241124732	2.576504600149e-09	miRNATAP	-0.267243460090773	1.17871192498365e-11	26512921	MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3		ovarian cancer
hsa-miR-3065-5p	AKT3	0.653308707552535	0.0999497219778851	-1.44031241124732	2.576504600149e-09	mirMAP	-0.18242132898273	2.34990243224026e-09		NA	NA	NA
hsa-miR-362-5p	AKT3	0.658947634569393	0.0243306847205756	-1.44031241124732	2.576504600149e-09	PITA;TargetScan;miRNATAP	-0.229571357984291	4.43564207755877e-09		NA	NA	NA
hsa-miR-542-3p	AKT3	1.62226640768239	2.6427102465476e-10	-1.44031241124732	2.576504600149e-09	miRanda	-0.186790699816246	1.44501888663791e-05		NA	NA	NA
hsa-miR-93-5p	AKT3	1.50844106515467	1.83836866996875e-12	-1.44031241124732	2.576504600149e-09	miRNATAP	-0.251105283811718	1.01733106411986e-06		NA	NA	NA
hsa-let-7a-5p	HRAS	-1.37014061604018	3.11451492971224e-14	0.139800610267073	0.358123351398595	miRNAWalker2_validate;miRTarBase	-0.142144334211175	0.000164893588817854	18344688;20033209;20607356;23134218;19323605	Using an established orthotopic mouse lung cancer model we show that intranasal let-7 administration reduces tumor formation in vivo in the lungs of animals expressing a G12D activating mutation for the K-ras oncogene;k-Ras and c-Myc two key oncogenes in lung cancer have been found to be targeted by let-7 in vitro; The aim of the present study is to determine the effect of let-7a a member of let-7 family on the growth of lung cancer in vivo and to investigate whether let-7-induced suppression of k-Ras and c-Myc is involved in lung cancer; Overexpression of let-7a can inhibit the growth of lung cancer transplanted subcutaneously in nude mice by suppression of k-Ras and c-Myc;Transfection of let-7 miRNA reduced expression of pan-RAS N-RAS and K-RAS in the glioblastoma cells;MicroRNA let 7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K Ras and HMGA2 gene expression; K-RAS and HMGA2 mRNA levels were significantly higher in the let-7a overexpressed group than those in the let-7a inhibited group p < 0.05; However the protein levels of K-RAS and HMGA2 were significantly lower in the let-7a overexpressed group than those in the let-7a inhibited group p < 0.05; We suppose that let-7a inhibits the proliferation and invasion of the cell line 95D by regulating the translation of K-RAS and HMGA2 mRNA not the transcription of the mRNA itself;Because let-7 microRNA targets the K-ras oncogene we aimed to characterize let-7 expression and function in PDAC in vitro and in vivo; Restoring let-7 levels in cancer-derived cell lines strongly inhibits cell proliferation K-ras expression and mitogen-activated protein kinase activation but fails to impede tumor growth progression after intratumoral gene transfer or after implantation of Capan-1 cells stably overexpressing let-7 microRNA	;;;;progression	lung cancer;lung cancer;glioblastoma;lung squamous cell cancer;pancreatic cancer
hsa-miR-143-3p	HRAS	-1.21021691908494	5.70938667332876e-06	0.139800610267073	0.358123351398595	miRNAWalker2_validate;miRTarBase	-0.125376896055055	1.11873626270013e-06	21276449	The Evi1 microRNA 143 K Ras axis in colon cancer		colon cancer
hsa-miR-940	JMJD7-PLA2G4B	0.011138136211269	0.974925352379525	-0.400430522628583	0.0339399904766164	miRNATAP	-0.117383627060937	1.87570641851953e-05		NA	NA	NA
hsa-miR-15a-5p	KDR	1.62575353599172	1.55312121019827e-19	-1.29217133319599	5.17137540720335e-06	miRNATAP	-0.277469551547698	8.30946725476635e-05		NA	NA	NA
hsa-miR-16-5p	KDR	0.749619098384047	4.11649450706988e-06	-1.29217133319599	5.17137540720335e-06	miRTarBase;miRNATAP	-0.302391399126077	0.000178613946334273	26934556	The expression levels of two target genes Myb and VEGFR2 were affected significantly by miR-16 while glucose administration inhibited miR-16 expression and enhanced tumor cell proliferation and migration; Hyperglycemia can impact the clinical outcomes of CRC patients likely by inhibiting miR-16 expression and the expression of its downstream genes Myb and VEGFR2		colorectal cancer
hsa-miR-19b-1-5p	KDR	1.71217036351784	3.28561659177495e-12	-1.29217133319599	5.17137540720335e-06	miRNAWalker2_validate	-0.215943064538471	0.000357453344573502		NA	NA	NA
hsa-miR-200c-3p	KDR	0.380533388300368	0.0842181838538353	-1.29217133319599	5.17137540720335e-06	miRNATAP	-0.266060212567765	8.13005514869735e-06	24205206	MiR 200c increases the radiosensitivity of non small cell lung cancer cell line A549 by targeting VEGF VEGFR2 pathway; MiR-200c at the nexus of epithelial-mesenchymal transition EMT is predicted to target VEGFR2; The purpose of this study is to test the hypothesis that regulation of VEGFR2 pathway by miR-200c could modulate the radiosensitivity of cancer cells; Bioinformatic analysis luciferase reporter assays and biochemical assays were carried out to validate VEGFR2 as a direct target of miR-200c; We identified VEGFR2 as a novel target of miR-200c		lung squamous cell cancer
hsa-miR-429	KDR	2.3794516574089	1.72813419703734e-13	-1.29217133319599	5.17137540720335e-06	PITA;miRanda;miRNATAP	-0.111419145999383	0.00975571919411248		NA	NA	NA
hsa-miR-590-3p	KDR	0.83851360565783	0.00129224433453587	-1.29217133319599	5.17137540720335e-06	miRanda	-0.242141052927696	5.91937848623311e-05		NA	NA	NA
hsa-miR-590-5p	KDR	2.07441240363458	4.95240551694843e-14	-1.29217133319599	5.17137540720335e-06	miRanda	-0.245958719964099	1.91688320565153e-05		NA	NA	NA
hsa-let-7a-3p	KRAS	0.167285443861993	0.431834813181487	0.538115716643554	0.00142410994615815	mirMAP;miRNATAP	-0.165605931792738	5.41329968030116e-05	24727325;20603437;24890702;23324806;21994416;23167843;27620744;20177422;25183481;22584434;18922928	Association study of the let 7 miRNA complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer NCCTG N0147 Clinical Trial; A let-7 microRNA-complementary site LCS6 polymorphism in the 3' untranslated region of the KRAS gene has been shown to disrupt let-7 binding and upregulate KRAS expression;A let 7 microRNA binding site polymorphism in 3' untranslated region of KRAS gene predicts response in wild type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy; A polymorphism in a let-7 microRNA complementary site lcs6 in the KRAS 3' untranslated region UTR is associated with an increased cancer risk in non-small-cell lung cancer and reduced overall survival OS in oral cancers; the presence of KRAS let-7 lcs6 polymorphism was evaluated in 130 mCRC patients who were enrolled in a phase II study of cetuximab monotherapy IMCL-0144; KRAS let-7 lcs6 polymorphism was found to be related to object response rate ORR in mCRC patients whose tumors had KRASwt;Let 7 microRNA binding site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta analysis; There is a small but growing body of literature regarding the predictive utility of a Let-7 microRNA-binding-site polymorphism in the 3'-untranslated region UTR of KRAS KRAS-LCS6 for colorectal cancer outcome although the results are conflicting; A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism LCS6; rs61764370 and colorectal cancer outcome;The LCS6 polymorphism in the binding site of let 7 microRNA to the KRAS 3' untranslated region: its role in the efficacy of anti EGFR based therapy in metastatic colorectal cancer patients; The lethal-7 let-7 family of microRNAs regulates KRAS activity; We studied the association of the KRAS let-7 LCS6 polymorphism with the response in 100 refractory mCRC patients treated with anti-EGFR antibodies; The KRAS let-7 LCS6 polymorphism was genotyped using the BioMark system in blood and tumor DNA samples; The KRAS let-7 LCS6 G-allele showed a statistically significant association with nonresponse to anti-EGFR-based treatment: 31.9% of patients with the T/T genotype presented a complete or a partial response versus no patients with T/G or G/G genotypes P=0.004;A let 7 microRNA SNP in the KRAS 3'UTR is prognostic in early stage colorectal cancer; Recently a SNP in a lethal-7 let-7 miRNA complementary site LCS6 in the KRAS 3'untranslated region was suggested to affect survival in metastatic CRC;Let 7 miRNA binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5 fluorouracil and oxaliplatin +/ cetuximab; Recent studies have reported associations between a variant allele in a let-7 microRNA complementary site LCS6 within the 3'untranslated region 3'UTR of KRAS rs61764370 and clinical outcome in metastatic colorectal cancer mCRC patients receiving cetuximab;A let 7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population; The let-7 microRNAs play a key role in regulating KRAS expression and a polymorphism in 3' untranslated region rs61764370 T/G of KRAS leads to its higher expression;Genetic modulation of the Let 7 microRNA binding to KRAS 3' untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab irinotecan; There is increasing evidence that the Let-7 microRNA miRNA exerts an effect as a tumor suppressor by targeting the KRAS mRNA; The Let-7 complementary site LCS6 T>G variant in the KRAS 3'-untranslated region weakens Let-7 binding;A let 7 microRNA binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy;High let 7a microRNA levels in KRAS mutated colorectal carcinomas may rescue anti EGFR therapy effects in patients with chemotherapy refractory metastatic disease; Preclinical and experimental data in vivo indicate that Lethal-7 Let-7 microRNA downregulates KRAS with antitumor effects in the presence of activating KRAS mutations; In 59 patients harboring KRAS mutations Let-7a levels were analyzed for association with overall survival OS and progression-free survival PFS times; An exploratory subgroup analysis was performed using the rs61764370 LCS6 T>G polymorphism that experimentally impairs Let-7 binding to KRAS mRNA; In patients with KRAS mutations Let-7a analysis may serve to identify subgroups of patients who may still benefit from EGFR inhibition and this may open up new perspectives for alternative treatment strategies;A SNP in a let 7 microRNA complementary site in the KRAS 3' untranslated region increases non small cell lung cancer risk; The purpose of this study was to identify single nucleotide polymorphisms SNP that could modify let-7 binding and to assess the effect of such SNPs on target gene regulation and risk for non-small cell lung cancer NSCLC let-7 complementary sites LCS were sequenced in the KRAS 3' untranslated region from 74 NSCLC cases to identify mutations and SNPs that correlated with NSCLC; The LCS6 variant allele in a KRAS miRANA complementary site is significantly associated with increased risk for NSCLC among moderate smokers and represents a new paradigm for let-7 miRNAs in lung cancer susceptibility	staging;drug resistance;poor survival;;drug resistance;staging;poor survival;;poor survival;poor survival;;progression;poor survival;	colon cancer;colorectal cancer;colorectal cancer;colorectal cancer;colorectal cancer;colorectal cancer;bladder cancer;colorectal cancer;colorectal cancer;colorectal cancer;lung squamous cell cancer
hsa-let-7b-3p	KRAS	-1.81889978084306	6.9913416210266e-19	0.538115716643554	0.00142410994615815	mirMAP;miRNATAP	-0.21045052897075	5.92266664846517e-09	24727325;20603437;24890702;23324806;21994416;23167843;27620744;20177422;25183481;26581910;22584434;26516699;18922928	Association study of the let 7 miRNA complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer NCCTG N0147 Clinical Trial; A let-7 microRNA-complementary site LCS6 polymorphism in the 3' untranslated region of the KRAS gene has been shown to disrupt let-7 binding and upregulate KRAS expression;A let 7 microRNA binding site polymorphism in 3' untranslated region of KRAS gene predicts response in wild type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy; A polymorphism in a let-7 microRNA complementary site lcs6 in the KRAS 3' untranslated region UTR is associated with an increased cancer risk in non-small-cell lung cancer and reduced overall survival OS in oral cancers; the presence of KRAS let-7 lcs6 polymorphism was evaluated in 130 mCRC patients who were enrolled in a phase II study of cetuximab monotherapy IMCL-0144; KRAS let-7 lcs6 polymorphism was found to be related to object response rate ORR in mCRC patients whose tumors had KRASwt;Let 7 microRNA binding site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta analysis; There is a small but growing body of literature regarding the predictive utility of a Let-7 microRNA-binding-site polymorphism in the 3'-untranslated region UTR of KRAS KRAS-LCS6 for colorectal cancer outcome although the results are conflicting; A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism LCS6; rs61764370 and colorectal cancer outcome;The LCS6 polymorphism in the binding site of let 7 microRNA to the KRAS 3' untranslated region: its role in the efficacy of anti EGFR based therapy in metastatic colorectal cancer patients; The lethal-7 let-7 family of microRNAs regulates KRAS activity; We studied the association of the KRAS let-7 LCS6 polymorphism with the response in 100 refractory mCRC patients treated with anti-EGFR antibodies; The KRAS let-7 LCS6 polymorphism was genotyped using the BioMark system in blood and tumor DNA samples; The KRAS let-7 LCS6 G-allele showed a statistically significant association with nonresponse to anti-EGFR-based treatment: 31.9% of patients with the T/T genotype presented a complete or a partial response versus no patients with T/G or G/G genotypes P=0.004;A let 7 microRNA SNP in the KRAS 3'UTR is prognostic in early stage colorectal cancer; Recently a SNP in a lethal-7 let-7 miRNA complementary site LCS6 in the KRAS 3'untranslated region was suggested to affect survival in metastatic CRC;Let 7 miRNA binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5 fluorouracil and oxaliplatin +/ cetuximab; Recent studies have reported associations between a variant allele in a let-7 microRNA complementary site LCS6 within the 3'untranslated region 3'UTR of KRAS rs61764370 and clinical outcome in metastatic colorectal cancer mCRC patients receiving cetuximab;A let 7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population; The let-7 microRNAs play a key role in regulating KRAS expression and a polymorphism in 3' untranslated region rs61764370 T/G of KRAS leads to its higher expression;Genetic modulation of the Let 7 microRNA binding to KRAS 3' untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab irinotecan; There is increasing evidence that the Let-7 microRNA miRNA exerts an effect as a tumor suppressor by targeting the KRAS mRNA; The Let-7 complementary site LCS6 T>G variant in the KRAS 3'-untranslated region weakens Let-7 binding;A let 7 microRNA binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy;Our results showed that miR-143 but not let-7b increased sensitization of KRAS mutant tumor cells to paclitaxel; Furthermore transfection of miR-143 but not let-7b mimic negatively regulated the expression of mutant but not wild-type KRAS;Preclinical and experimental data in vivo indicate that Lethal-7 Let-7 microRNA downregulates KRAS with antitumor effects in the presence of activating KRAS mutations; An exploratory subgroup analysis was performed using the rs61764370 LCS6 T>G polymorphism that experimentally impairs Let-7 binding to KRAS mRNA;Interestingly the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression;A SNP in a let 7 microRNA complementary site in the KRAS 3' untranslated region increases non small cell lung cancer risk; The purpose of this study was to identify single nucleotide polymorphisms SNP that could modify let-7 binding and to assess the effect of such SNPs on target gene regulation and risk for non-small cell lung cancer NSCLC let-7 complementary sites LCS were sequenced in the KRAS 3' untranslated region from 74 NSCLC cases to identify mutations and SNPs that correlated with NSCLC; The LCS6 variant allele in a KRAS miRANA complementary site is significantly associated with increased risk for NSCLC among moderate smokers and represents a new paradigm for let-7 miRNAs in lung cancer susceptibility	staging;drug resistance;poor survival;;drug resistance;staging;poor survival;;poor survival;poor survival;;;;;	colon cancer;colorectal cancer;colorectal cancer;colorectal cancer;colorectal cancer;colorectal cancer;bladder cancer;colorectal cancer;colorectal cancer;colorectal cancer;colorectal cancer;pancreatic cancer;lung squamous cell cancer
hsa-miR-1-3p	KRAS	-1.48412019995919	0.000242034342580425	0.538115716643554	0.00142410994615815	MirTarget	-0.1135101654678	3.65182035802432e-08		NA	NA	NA
hsa-miR-126-3p	KRAS	0.397563736477277	0.115641762947829	0.538115716643554	0.00142410994615815	miRNAWalker2_validate;miRTarBase	-0.140662247102959	4.48695871977096e-06	22845403	miR-126 is also known to target other crucial oncogenes in PDAC such as KRAS and CRK		pancreatic cancer
hsa-miR-1271-5p	KRAS	-0.0172769786790662	0.951102370899887	0.538115716643554	0.00142410994615815	MirTarget	-0.111352851066065	6.81606802337118e-05		NA	NA	NA
hsa-miR-140-3p	KRAS	-1.11373309124537	8.35257079443689e-14	0.538115716643554	0.00142410994615815	MirTarget	-0.379051955627805	3.51513569284386e-14		NA	NA	NA
hsa-miR-155-5p	KRAS	0.813513839059142	0.000608282725633232	0.538115716643554	0.00142410994615815	miRNAWalker2_validate;miRNATAP	-0.136672576377435	2.71388112053399e-05		NA	NA	NA
hsa-miR-16-1-3p	KRAS	1.50034693398929	6.63958242991125e-10	0.538115716643554	0.00142410994615815	mirMAP	-0.120692099076156	0.0020633534672843		NA	NA	NA
hsa-miR-181a-5p	KRAS	-0.375429731222937	0.0562142867129802	0.538115716643554	0.00142410994615815	miRNAWalker2_validate	-0.232892392323763	2.90389285591447e-09	24098024;27517749;26124189	The KRAS mutational status was determined by pyrosequencing and miR-181a expression was measured by quantitative RT-PCR in CRC tumour tissue and corresponding non-neoplastic colon tissue;Here we report that miR-181a directly binds to 3'-untranslated regions UTRs; downregulates KRAS NRAS and MAPK1; and decreases AML growth; The delivery of miR-181a mimics to target AML cells using transferrin-targeting lipopolyplex nanoparticles NP increased mature miR-181a; downregulated KRAS NRAS and MAPK1; and resulted in decreased phosphorylation of the downstream RAS effectors;MiR 181a 5p inhibits cell proliferation and migration by targeting Kras in non small cell lung cancer A549 cells; Luciferase activity assay results demonstrated that two binding sites of Kras could be directly targeted by miR-181a-5p; Furthermore Kras was down-regulated by miR-181a-5p at both transcriptional and translational levels; SiRNA-mediated Kras down-regulation could mimic the effects of miR-181a-5p mimic in A549 cells; Our findings suggest that miR-181a-5p plays a potential role in tumor suppression by partially targeting Kras and has the potential therapeutic application in NSCLC patients	;;	colorectal cancer;acute myeloid leukemia;lung squamous cell cancer
hsa-miR-181c-5p	KRAS	0.529875814537156	0.0125885822998008	0.538115716643554	0.00142410994615815	miRNAWalker2_validate;miRTarBase	-0.113481461651682	0.00199940913466899		NA	NA	NA
hsa-miR-186-5p	KRAS	0.852175445703945	6.88885738584309e-10	0.538115716643554	0.00142410994615815	mirMAP	-0.173206213582145	0.0020136892983084		NA	NA	NA
hsa-miR-193a-3p	KRAS	0.549173467360291	0.0319030569365466	0.538115716643554	0.00142410994615815	MirTarget;miRanda;miRNATAP	-0.114033878061734	0.000545245334645599		NA	NA	NA
hsa-miR-193a-5p	KRAS	-1.15938257046946	2.61709321247277e-08	0.538115716643554	0.00142410994615815	miRNATAP	-0.136206451672479	0.000220728848496		NA	NA	NA
hsa-miR-195-3p	KRAS	-1.33068822339418	6.65427393047357e-09	0.538115716643554	0.00142410994615815	mirMAP	-0.26052009331858	1.37547972270525e-15		NA	NA	NA
hsa-miR-199a-5p	KRAS	1.3057193856884	2.38429382751645e-08	0.538115716643554	0.00142410994615815	miRanda;miRNATAP	-0.190569403157002	4.12804905993219e-09		NA	NA	NA
hsa-miR-199b-5p	KRAS	2.13822205171062	4.56262988762436e-15	0.538115716643554	0.00142410994615815	miRanda;miRNATAP	-0.160083363830103	4.62674745647173e-09	27517624	The miR-199b prognostic impact was particularly evident in both younger and KRAS wild-type subgroups		colorectal cancer
hsa-miR-224-3p	KRAS	0.921090817288022	0.010010047721564	0.538115716643554	0.00142410994615815	mirMAP	-0.11580794239374	2.34601235413632e-07	25919696	MicroRNA 224 is associated with colorectal cancer progression and response to 5 fluorouracil based chemotherapy by KRAS dependent and independent mechanisms; MicroRNA-224 was differentially expressed in dysplastic colorectal disease and in isogeneic KRAS WT and mutant HCT116 cells; 5-FU chemosensitivity was significantly increased in miR-224 knockdown cells and in NIH3T3 cells expressing KRAS and BRAF mutant proteins	progression;drug resistance	colorectal cancer
hsa-miR-27b-3p	KRAS	0.236438984240408	0.12263510345883	0.538115716643554	0.00142410994615815	miRNATAP	-0.140671332847896	0.00626162133896643		NA	NA	NA
hsa-miR-30a-3p	KRAS	-2.54042202792785	2.9111625410859e-18	0.538115716643554	0.00142410994615815	MirTarget;miRNATAP	-0.122460927678546	1.58218389307393e-06		NA	NA	NA
hsa-miR-30a-5p	KRAS	-0.924084264430689	0.000762030454634728	0.538115716643554	0.00142410994615815	mirMAP;miRNATAP	-0.160923145065632	7.88859261457886e-09		NA	NA	NA
hsa-miR-30b-5p	KRAS	0.358144314839612	0.138026229059594	0.538115716643554	0.00142410994615815	mirMAP;miRNATAP	-0.147252408030935	4.51771159246383e-06		NA	NA	NA
hsa-miR-30c-5p	KRAS	-0.327319105755825	0.123595832152687	0.538115716643554	0.00142410994615815	mirMAP;miRNATAP	-0.303491851342304	1.38338910293015e-17	22701724	Deregulated miRNAs in hereditary breast cancer revealed a role for miR 30c in regulating KRAS oncogene; In particular we experimentally validated KRAS as a miR-30c target; Luciferase assays confirmed that miR-30c binds the 3'UTR of KRAS transcripts and expression of pre-miR-30c down-regulated KRAS mRNA and protein; In addition we provide evidence that KRAS is a target of miR-30c and that this miRNA suppresses breast cancer cell growth potentially through inhibition of KRAS signaling		breast cancer
hsa-miR-30d-3p	KRAS	0.00396376345349925	0.986457040013182	0.538115716643554	0.00142410994615815	MirTarget;miRNATAP	-0.12073831042602	0.00128170411687249		NA	NA	NA
hsa-miR-30d-5p	KRAS	-0.920901858717441	3.50898334321668e-05	0.538115716643554	0.00142410994615815	mirMAP;miRNATAP	-0.124035278299491	0.000357846902820112		NA	NA	NA
hsa-miR-30e-3p	KRAS	-0.104420043859122	0.526240453209293	0.538115716643554	0.00142410994615815	MirTarget	-0.254543853548427	7.09600327106139e-08		NA	NA	NA
hsa-miR-30e-5p	KRAS	1.60414100786743	3.78951090573667e-19	0.538115716643554	0.00142410994615815	mirMAP;miRNATAP	-0.125942634043968	0.00267795482717309		NA	NA	NA
hsa-miR-501-3p	KRAS	-0.0405952693028064	0.866802243505833	0.538115716643554	0.00142410994615815	MirTarget;PITA;TargetScan;miRNATAP	-0.124338029852589	0.000111299015637681		NA	NA	NA
hsa-miR-502-3p	KRAS	-0.262270070977708	0.161760375279961	0.538115716643554	0.00142410994615815	MirTarget;PITA;miRNATAP	-0.116432061546502	0.00538025775498572		NA	NA	NA
hsa-miR-532-5p	KRAS	0.576620898517708	0.0023245812680956	0.538115716643554	0.00142410994615815	MirTarget;PITA;miRNATAP	-0.123485597460216	0.00273306142385404		NA	NA	NA
hsa-miR-30c-5p	MAP2K1	-0.327319105755825	0.123595832152687	-0.126507255559492	0.255813608366235	miRNAWalker2_validate	-0.148243346155614	3.94199903529302e-10		NA	NA	NA
hsa-miR-497-5p	MAP2K1	-0.0546347378264729	0.786205564901684	-0.126507255559492	0.255813608366235	miRNAWalker2_validate	-0.146950542279665	4.9483059880063e-09		NA	NA	NA
hsa-miR-130a-3p	MAPK1	0.881660100597014	0.000158893668519248	-0.313704159534906	0.0065740365500908	mirMAP	-0.101872197195	5.97373126035408e-06		NA	NA	NA
hsa-miR-140-5p	MAPK1	0.669142684153918	0.000335928403032308	-0.313704159534906	0.0065740365500908	miRanda	-0.105360739553965	0.000299450445528468		NA	NA	NA
hsa-miR-148a-3p	MAPK1	2.30885799126944	1.95226081368985e-21	-0.313704159534906	0.0065740365500908	mirMAP	-0.102558880400122	7.51166113357563e-07		NA	NA	NA
hsa-miR-24-1-5p	MAPK1	0.856025727237819	0.000107354490323658	-0.313704159534906	0.0065740365500908	mirMAP	-0.114103342147363	5.37066958548902e-06		NA	NA	NA
hsa-miR-29a-5p	MAPK1	1.89519956688438	1.03453349363915e-11	-0.313704159534906	0.0065740365500908	mirMAP	-0.100646824836984	5.49015969248301e-06		NA	NA	NA
hsa-miR-29b-3p	MAPK1	3.10527711861309	3.01242507282711e-32	-0.313704159534906	0.0065740365500908	mirMAP	-0.122356815748067	3.56933939779318e-11		NA	NA	NA
hsa-miR-342-3p	MAPK1	-0.128691966564961	0.561034080130801	-0.313704159534906	0.0065740365500908	miRanda;mirMAP	-0.137175460423021	7.76879946497687e-09		NA	NA	NA
hsa-miR-34a-5p	MAPK1	1.40588612517769	8.60097477768592e-12	-0.313704159534906	0.0065740365500908	mirMAP	-0.105828142272272	2.59913448288353e-05		NA	NA	NA
hsa-miR-454-3p	MAPK1	1.49453641052169	4.46235742871434e-09	-0.313704159534906	0.0065740365500908	mirMAP	-0.104171229052281	2.01455003951624e-05		NA	NA	NA
hsa-miR-128-3p	MAPKAPK3	1.03509868349735	2.11606310588315e-10	-0.348682372957655	0.0255209675217176	MirTarget	-0.213442860654922	7.98428808357436e-07		NA	NA	NA
hsa-miR-421	MAPKAPK3	0.170525317701774	0.535277026680289	-0.348682372957655	0.0255209675217176	miRanda	-0.105470928337545	0.000199541167159307		NA	NA	NA
hsa-miR-130b-5p	NFAT5	1.53645187062942	1.10498816261505e-08	-0.409853693095821	0.00241772915052018	MirTarget;miRNATAP	-0.108561642446117	1.60834322577139e-06		NA	NA	NA
hsa-miR-132-3p	NFAT5	0.0122601212105202	0.934032846062939	-0.409853693095821	0.00241772915052018	miRNATAP	-0.12963519248744	0.00233856127647591		NA	NA	NA
hsa-miR-148b-3p	NFAT5	0.483970528590224	0.0026495409465901	-0.409853693095821	0.00241772915052018	miRNATAP	-0.112577222828241	0.0038126543774256		NA	NA	NA
hsa-miR-27b-5p	NFAT5	1.03511957999268	7.86187917705303e-11	-0.409853693095821	0.00241772915052018	miRNATAP	-0.16192960419066	2.57829034468637e-05		NA	NA	NA
hsa-miR-590-3p	NFAT5	0.83851360565783	0.00129224433453587	-0.409853693095821	0.00241772915052018	MirTarget;miRanda;mirMAP;miRNATAP	-0.115936168805103	4.65917004279092e-05		NA	NA	NA
hsa-miR-590-5p	NFAT5	2.07441240363458	4.95240551694843e-14	-0.409853693095821	0.00241772915052018	PITA;mirMAP;miRNATAP	-0.125507198595402	3.73504850114134e-06		NA	NA	NA
hsa-miR-93-5p	NFAT5	1.50844106515467	1.83836866996875e-12	-0.409853693095821	0.00241772915052018	MirTarget;miRNATAP	-0.118263351694996	2.99203468201362e-05		NA	NA	NA
hsa-miR-3127-5p	NFATC1	0.382717393698386	0.11535780874721	-1.1375752288108	4.2403023117592e-09	MirTarget	-0.111363856377225	0.00286268272528884		NA	NA	NA
hsa-miR-421	NFATC1	0.170525317701774	0.535277026680289	-1.1375752288108	4.2403023117592e-09	miRanda	-0.27250878649941	5.59172029209645e-15		NA	NA	NA
hsa-miR-130b-5p	NFATC2	1.53645187062942	1.10498816261505e-08	-1.17929519652878	0.000402858371584528	MirTarget	-0.172861973245698	0.00221822037960357		NA	NA	NA
hsa-miR-182-5p	NFATC2	3.21839823004635	5.13049145201115e-39	-1.17929519652878	0.000402858371584528	mirMAP	-0.180422957533554	0.00169761028088969		NA	NA	NA
hsa-miR-185-5p	NFATC2	1.14291034858482	2.95777119743491e-13	-1.17929519652878	0.000402858371584528	MirTarget	-0.360674698099435	0.00018867412489729		NA	NA	NA
hsa-miR-186-5p	NFATC2	0.852175445703945	6.88885738584309e-10	-1.17929519652878	0.000402858371584528	mirMAP	-0.343079979359603	0.00202223937894896		NA	NA	NA
hsa-miR-19a-3p	NFATC2	2.11776595911517	7.07663078397156e-10	-1.17929519652878	0.000402858371584528	mirMAP	-0.336569537886002	7.83772096103092e-11		NA	NA	NA
hsa-miR-19b-3p	NFATC2	2.10868505662119	5.40846613768389e-17	-1.17929519652878	0.000402858371584528	mirMAP	-0.37856857138205	7.5498987798628e-10		NA	NA	NA
hsa-miR-2355-3p	NFATC2	1.10676344164715	6.24068383465151e-06	-1.17929519652878	0.000402858371584528	mirMAP	-0.219356663156956	0.000875934214021124		NA	NA	NA
hsa-miR-29a-5p	NFATC2	1.89519956688438	1.03453349363915e-11	-1.17929519652878	0.000402858371584528	mirMAP;miRNATAP	-0.177982407502831	0.00605902966456155		NA	NA	NA
hsa-miR-30b-5p	NFATC2	0.358144314839612	0.138026229059594	-1.17929519652878	0.000402858371584528	MirTarget;mirMAP	-0.200783588972738	0.00170730601229697		NA	NA	NA
hsa-miR-3613-5p	NFATC2	0.0237159233591191	0.934730899070298	-1.17929519652878	0.000402858371584528	mirMAP	-0.24336416775385	0.000133096294572765		NA	NA	NA
hsa-miR-590-3p	NFATC2	0.83851360565783	0.00129224433453587	-1.17929519652878	0.000402858371584528	mirMAP	-0.264991647100287	0.000176914211247844		NA	NA	NA
hsa-miR-9-5p	NFATC2	4.99250901331516	2.59132733422801e-19	-1.17929519652878	0.000402858371584528	MirTarget	-0.105804655043001	6.44752588454657e-05		NA	NA	NA
hsa-miR-15a-5p	NFATC3	1.62575353599172	1.55312121019827e-19	-0.775339809160321	2.42596775036985e-09	MirTarget;miRNATAP	-0.194760431797607	1.31515520866454e-09		NA	NA	NA
hsa-miR-185-5p	NFATC3	1.14291034858482	2.95777119743491e-13	-0.775339809160321	2.42596775036985e-09	MirTarget;miRNATAP	-0.243443371940348	7.87569812717632e-11		NA	NA	NA
hsa-miR-21-3p	NFATC3	2.54206008030157	1.11598785398763e-30	-0.775339809160321	2.42596775036985e-09	MirTarget	-0.144436369277164	1.38631470692728e-08		NA	NA	NA
hsa-miR-29b-3p	NFATC3	3.10527711861309	3.01242507282711e-32	-0.775339809160321	2.42596775036985e-09	MirTarget;miRNATAP	-0.113008786184003	1.1536763111009e-07		NA	NA	NA
hsa-miR-335-3p	NFATC3	1.51116383169018	6.88553098788624e-13	-0.775339809160321	2.42596775036985e-09	mirMAP	-0.104848301816004	0.000194709438293604		NA	NA	NA
hsa-miR-589-3p	NFATC3	1.34253876396688	1.84935927493927e-05	-0.775339809160321	2.42596775036985e-09	mirMAP	-0.123021593670604	2.81638805309194e-10		NA	NA	NA
hsa-miR-590-3p	NFATC3	0.83851360565783	0.00129224433453587	-0.775339809160321	2.42596775036985e-09	miRanda	-0.142048821132892	2.6995336752082e-07		NA	NA	NA
hsa-miR-185-3p	NFATC4	-0.377490365509078	0.093653288903368	0.936688963651323	2.59723598381625e-05	MirTarget	-0.154954243253114	0.00074408877001007		NA	NA	NA
hsa-miR-423-5p	NFATC4	-1.80309342242719	1.34791344187441e-19	0.936688963651323	2.59723598381625e-05	miRNATAP	-0.21075464541514	2.27046521867108e-05		NA	NA	NA
hsa-miR-145-5p	NRAS	-1.34926078156437	2.63526538800669e-07	0.110922789912811	0.412920190999736	miRNAWalker2_validate;MirTarget;miRNATAP	-0.142760374746012	6.05977027346954e-10	26973415	miR-145 expression was significantly downregulated in colon cancer tissues with its expression in normal colonic tissues being 4-5-fold higher two sample t test P < 0.05 whereas N-ras expression showed the opposite trend		colon cancer
hsa-miR-148a-3p	NRAS	2.30885799126944	1.95226081368985e-21	0.110922789912811	0.412920190999736	MirTarget	-0.109343012733505	6.98144190286614e-06		NA	NA	NA
hsa-miR-195-3p	NRAS	-1.33068822339418	6.65427393047357e-09	0.110922789912811	0.412920190999736	mirMAP	-0.160994991063139	1.05944502094987e-09		NA	NA	NA
hsa-miR-22-3p	NRAS	1.42501909916631	1.72295005910055e-25	0.110922789912811	0.412920190999736	MirTarget;miRNATAP	-0.128848632159027	0.00314401368706814		NA	NA	NA
hsa-miR-26b-5p	NRAS	0.72362441215247	4.7794659748036e-05	0.110922789912811	0.412920190999736	mirMAP;miRNATAP	-0.130094780209659	0.000185700963505737		NA	NA	NA
hsa-miR-27b-3p	NRAS	0.236438984240408	0.12263510345883	0.110922789912811	0.412920190999736	miRNATAP	-0.154582178613336	0.000157756473886806		NA	NA	NA
hsa-miR-29a-3p	NRAS	0.101650412194573	0.573201097011668	0.110922789912811	0.412920190999736	miRNATAP	-0.156058827596967	6.08074898827527e-06		NA	NA	NA
hsa-miR-29b-3p	NRAS	3.10527711861309	3.01242507282711e-32	0.110922789912811	0.412920190999736	miRNATAP	-0.130094390329954	2.14950403130123e-09		NA	NA	NA
hsa-miR-29c-3p	NRAS	1.32354490728858	1.84279305179762e-07	0.110922789912811	0.412920190999736	miRNATAP	-0.132620598651339	2.93062944029642e-08		NA	NA	NA
hsa-miR-320a	NRAS	-0.961144925954715	1.62478794429204e-08	0.110922789912811	0.412920190999736	mirMAP	-0.138653847620251	0.000123789780187142		NA	NA	NA
hsa-miR-502-3p	NRAS	-0.262270070977708	0.161760375279961	0.110922789912811	0.412920190999736	MirTarget	-0.116067692488029	0.000491333225482351		NA	NA	NA
hsa-miR-664a-3p	NRAS	0.443077463053857	0.0214248925850984	0.110922789912811	0.412920190999736	MirTarget	-0.339669060778621	8.1321923374988e-29		NA	NA	NA
hsa-miR-186-5p	PIK3CA	0.852175445703945	6.88885738584309e-10	-0.335143841150832	0.0107695904000801	mirMAP	-0.158211833933772	0.000271764939125213		NA	NA	NA
hsa-miR-501-5p	PIK3CA	0.411357595674671	0.10435288464149	-0.335143841150832	0.0107695904000801	mirMAP	-0.12161859871495	2.80222388365699e-07		NA	NA	NA
hsa-miR-96-5p	PIK3CA	3.0381097138467	4.40362891630201e-24	-0.335143841150832	0.0107695904000801	TargetScan	-0.126074442438012	7.26672594996813e-09		NA	NA	NA
hsa-miR-454-3p	PIK3CB	1.49453641052169	4.46235742871434e-09	0.0520424688078016	0.708498300848208	miRNATAP	-0.107092855274913	0.000279808925292599		NA	NA	NA
hsa-miR-421	PIK3CD	0.170525317701774	0.535277026680289	-0.165252183051274	0.400815192488832	miRanda	-0.187035284767016	1.2803934448503e-07		NA	NA	NA
hsa-miR-148b-3p	PIK3CG	0.483970528590224	0.0026495409465901	-1.19325793461087	5.28114748039233e-05	miRNAWalker2_validate	-0.239430332797948	0.00515332606189168		NA	NA	NA
hsa-miR-26b-5p	PIK3CG	0.72362441215247	4.7794659748036e-05	-1.19325793461087	5.28114748039233e-05	miRNAWalker2_validate	-0.285401672500096	0.000198071700272844		NA	NA	NA
hsa-miR-29b-3p	PIK3CG	3.10527711861309	3.01242507282711e-32	-1.19325793461087	5.28114748039233e-05	miRTarBase	-0.13454994451672	0.00563635188925694		NA	NA	NA
hsa-miR-335-3p	PIK3CG	1.51116383169018	6.88553098788624e-13	-1.19325793461087	5.28114748039233e-05	mirMAP	-0.273824058387904	1.51960031354635e-05		NA	NA	NA
hsa-miR-542-3p	PIK3CG	1.62226640768239	2.6427102465476e-10	-1.19325793461087	5.28114748039233e-05	miRanda	-0.188110029792226	0.000315799878113487		NA	NA	NA
hsa-miR-106a-5p	PIK3R1	1.3902608059488	6.07931522284525e-05	-1.28526113405546	1.1596112892202e-14	MirTarget;miRNATAP	-0.152594260668069	8.26964346589391e-10		NA	NA	NA
hsa-miR-106b-5p	PIK3R1	1.47447672652218	1.32004094930462e-13	-1.28526113405546	1.1596112892202e-14	MirTarget;miRNATAP	-0.274486784039244	3.92361901886501e-13		NA	NA	NA
hsa-miR-128-3p	PIK3R1	1.03509868349735	2.11606310588315e-10	-1.28526113405546	1.1596112892202e-14	MirTarget	-0.262733562571172	2.81828198129055e-08	25962360	miR 128 3p suppresses hepatocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patients; Mechanistically miR-128-3p was confirmed to regulate PIK3R1 p85α expression thereby suppressing phosphatidylinositol 3-kinase PI3K/AKT pathway activation using qRT-PCR and western blot analysis; Hence we conclude that miR-128-3p which is frequently downregulated in HCC inhibits HCC progression by regulating PIK3R1 and PI3K/AKT activation and is a prognostic marker for HCC patients	worse prognosis;progression	liver cancer
hsa-miR-1301-3p	PIK3R1	0.845987603184611	0.000579808501723616	-1.28526113405546	1.1596112892202e-14	MirTarget	-0.252566507630763	3.89638206850943e-16		NA	NA	NA
hsa-miR-15a-5p	PIK3R1	1.62575353599172	1.55312121019827e-19	-1.28526113405546	1.1596112892202e-14	MirTarget	-0.198845640675418	2.2459439580454e-06		NA	NA	NA
hsa-miR-16-2-3p	PIK3R1	0.503964803530872	0.0263648405197492	-1.28526113405546	1.1596112892202e-14	MirTarget	-0.215346374588015	7.85659740371802e-09		NA	NA	NA
hsa-miR-16-5p	PIK3R1	0.749619098384047	4.11649450706988e-06	-1.28526113405546	1.1596112892202e-14	MirTarget	-0.14663084031301	0.00245632583144358		NA	NA	NA
hsa-miR-17-5p	PIK3R1	2.07078488653279	2.77403038572568e-19	-1.28526113405546	1.1596112892202e-14	MirTarget;TargetScan;miRNATAP	-0.30827377198364	1.00416866782136e-22		NA	NA	NA
hsa-miR-182-5p	PIK3R1	3.21839823004635	5.13049145201115e-39	-1.28526113405546	1.1596112892202e-14	miRNATAP	-0.153577568348738	1.31399000956901e-07		NA	NA	NA
hsa-miR-185-5p	PIK3R1	1.14291034858482	2.95777119743491e-13	-1.28526113405546	1.1596112892202e-14	miRNATAP	-0.266123472564886	5.49627003455298e-08		NA	NA	NA
hsa-miR-186-5p	PIK3R1	0.852175445703945	6.88885738584309e-10	-1.28526113405546	1.1596112892202e-14	mirMAP	-0.266496146428416	2.3226235073163e-06		NA	NA	NA
hsa-miR-200c-3p	PIK3R1	0.380533388300368	0.0842181838538353	-1.28526113405546	1.1596112892202e-14	mirMAP	-0.174738637328334	9.22364461849854e-07		NA	NA	NA
hsa-miR-20a-5p	PIK3R1	2.64649625616975	5.1469418982085e-27	-1.28526113405546	1.1596112892202e-14	MirTarget;miRNATAP	-0.268255645046992	2.93530513676098e-20		NA	NA	NA
hsa-miR-21-5p	PIK3R1	4.38165933891779	1.52536633902505e-92	-1.28526113405546	1.1596112892202e-14	miRNAWalker2_validate;MirTarget;miRNATAP	-0.239855941401679	1.66617444081141e-16	26676464	PIK3R1 targeting by miR 21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT and predicts clinical outcome of breast cancer; Next we identified the PIK3R1 as a direct target of miR-21 and showed that it was negatively regulated by miR-21; Taken together we provide novel evidence that miR-21 knockdown suppresses cell growth migration and invasion partly by inhibiting PI3K/AKT activation via direct targeting PIK3R1 and reversing EMT in breast cancer	cell migration	breast cancer
hsa-miR-22-5p	PIK3R1	1.71436244278242	9.85038001236064e-15	-1.28526113405546	1.1596112892202e-14	mirMAP	-0.249170402831725	1.77307790115702e-13		NA	NA	NA
hsa-miR-29b-3p	PIK3R1	3.10527711861309	3.01242507282711e-32	-1.28526113405546	1.1596112892202e-14	MirTarget;miRNATAP	-0.169264704761152	8.1620915503371e-10		NA	NA	NA
hsa-miR-335-3p	PIK3R1	1.51116383169018	6.88553098788624e-13	-1.28526113405546	1.1596112892202e-14	mirMAP	-0.174731000503181	1.56931158200611e-06		NA	NA	NA
hsa-miR-424-5p	PIK3R1	1.26485330287919	6.1498991028257e-06	-1.28526113405546	1.1596112892202e-14	MirTarget	-0.120660860108298	1.41199550729587e-05		NA	NA	NA
hsa-miR-450b-5p	PIK3R1	1.69248953402469	1.96052058003353e-07	-1.28526113405546	1.1596112892202e-14	miRNATAP	-0.105483872062601	7.60035078150308e-05		NA	NA	NA
hsa-miR-582-5p	PIK3R1	1.08286181406653	0.00149040450161757	-1.28526113405546	1.1596112892202e-14	mirMAP	-0.121659359408152	1.98808465862233e-07		NA	NA	NA
hsa-miR-589-3p	PIK3R1	1.34253876396688	1.84935927493927e-05	-1.28526113405546	1.1596112892202e-14	mirMAP	-0.110115880585781	1.73041185531321e-05		NA	NA	NA
hsa-miR-590-3p	PIK3R1	0.83851360565783	0.00129224433453587	-1.28526113405546	1.1596112892202e-14	miRanda;mirMAP	-0.21433969556349	1.93094554722457e-09		NA	NA	NA
hsa-miR-590-5p	PIK3R1	2.07441240363458	4.95240551694843e-14	-1.28526113405546	1.1596112892202e-14	MirTarget;PITA;miRanda;miRNATAP	-0.297606057222883	4.39734655384069e-19		NA	NA	NA
hsa-miR-629-3p	PIK3R1	1.31892116211001	0.000114487182853678	-1.28526113405546	1.1596112892202e-14	MirTarget	-0.155200085033098	2.2200629415611e-10		NA	NA	NA
hsa-miR-93-5p	PIK3R1	1.50844106515467	1.83836866996875e-12	-1.28526113405546	1.1596112892202e-14	MirTarget;miRNATAP	-0.302548872464343	3.62432128460294e-18		NA	NA	NA
hsa-miR-96-5p	PIK3R1	3.0381097138467	4.40362891630201e-24	-1.28526113405546	1.1596112892202e-14	TargetScan;miRNATAP	-0.247820034174453	4.28366535969023e-19		NA	NA	NA
hsa-miR-29b-1-5p	PIK3R3	1.71024742617744	3.64915691793611e-09	-0.993075734580867	1.37876508579496e-06	mirMAP	-0.137607471527013	2.02669327816331e-05		NA	NA	NA
hsa-miR-335-3p	PIK3R3	1.51116383169018	6.88553098788624e-13	-0.993075734580867	1.37876508579496e-06	mirMAP	-0.239450639911665	5.21180596069304e-08		NA	NA	NA
hsa-miR-107	PIK3R5	0.658676029898313	5.11480446318819e-07	-1.41857329052665	4.9150449517908e-09	miRanda	-0.303365993068523	0.000471196296141979		NA	NA	NA
hsa-miR-182-5p	PIK3R5	3.21839823004635	5.13049145201115e-39	-1.41857329052665	4.9150449517908e-09	MirTarget	-0.327566926397612	1.58877421029473e-15		NA	NA	NA
hsa-miR-142-5p	PLA2G12A	1.29672439149353	4.0768822158894e-06	-0.0788546181881973	0.499158564786441	mirMAP	-0.131800396566356	4.84970998647658e-11		NA	NA	NA
hsa-miR-150-5p	PLA2G12A	-0.702328520623782	0.0215316651134431	-0.0788546181881973	0.499158564786441	mirMAP	-0.109476263552952	1.80094060108042e-10		NA	NA	NA
hsa-miR-28-5p	PLA2G1B	1.19639196514745	4.59365801666536e-18	-4.65869434494303	5.92632211074147e-12	miRanda	-0.714163430019852	0.00154176723606543		NA	NA	NA
hsa-miR-1976	PLA2G2F	-1.27772236648866	7.13245221784788e-10	1.85239250918301	0.000408421370733288	mirMAP	-0.412433519219505	0.000339748244121928		NA	NA	NA
hsa-miR-532-5p	PLA2G2F	0.576620898517708	0.0023245812680956	1.85239250918301	0.000408421370733288	mirMAP	-0.384692781015398	0.00274632142999211		NA	NA	NA
hsa-miR-450b-5p	PLA2G3	1.69248953402469	1.96052058003353e-07	-3.26398420302921	7.81993892455061e-08	miRNATAP	-0.430421579056939	6.90748646882128e-06		NA	NA	NA
hsa-miR-452-3p	PLA2G3	0.477736876273128	0.22218404598603	-3.26398420302921	7.81993892455061e-08	MirTarget	-0.255221077598253	0.00248457917549569		NA	NA	NA
hsa-miR-146b-5p	PLA2G4A	1.0922867893808	5.63754607494775e-06	1.23139708452911	0.00360064815222154	miRNAWalker2_validate	-0.539646016767087	8.49384554342977e-12		NA	NA	NA
hsa-miR-30a-5p	PLA2G4A	-0.924084264430689	0.000762030454634728	1.23139708452911	0.00360064815222154	miRNAWalker2_validate	-0.337988397444713	1.56392399647892e-06		NA	NA	NA
hsa-miR-361-5p	PLA2G4A	0.21454431962475	0.0800957579368424	1.23139708452911	0.00360064815222154	miRanda	-0.455000317938252	0.005160776853399		NA	NA	NA
hsa-miR-374a-5p	PLA2G4A	-0.197027254874826	0.298080902192861	1.23139708452911	0.00360064815222154	mirMAP	-0.384602231876405	0.000945916552995376		NA	NA	NA
hsa-miR-450b-5p	PLA2G4E	1.69248953402469	1.96052058003353e-07	-0.723776164951995	0.201279307414008	mirMAP	-0.353591315163214	6.01448410118293e-05		NA	NA	NA
hsa-miR-128-3p	PLA2G5	1.03509868349735	2.11606310588315e-10	-1.52854910719925	3.60899705613865e-08	miRNAWalker2_validate	-0.463850459902729	2.23760548419397e-09		NA	NA	NA
hsa-miR-330-5p	PLA2G5	0.168520831101569	0.336433937906706	-1.52854910719925	3.60899705613865e-08	miRanda	-0.308708237234084	3.20106460280176e-05		NA	NA	NA
hsa-miR-429	PLA2G5	2.3794516574089	1.72813419703734e-13	-1.52854910719925	3.60899705613865e-08	miRanda	-0.178077576146297	2.39509849764538e-05		NA	NA	NA
hsa-miR-590-5p	PLA2G5	2.07441240363458	4.95240551694843e-14	-1.52854910719925	3.60899705613865e-08	miRanda	-0.21637478398772	0.000135984222229852		NA	NA	NA
hsa-miR-185-3p	PLA2G6	-0.377490365509078	0.093653288903368	0.476315859876846	0.0705352394789323	MirTarget	-0.267493284551792	5.88524200603373e-07		NA	NA	NA
hsa-miR-30a-3p	PLA2G6	-2.54042202792785	2.9111625410859e-18	0.476315859876846	0.0705352394789323	miRNATAP	-0.146668786631899	0.000240180915888741		NA	NA	NA
hsa-miR-423-5p	PLA2G6	-1.80309342242719	1.34791344187441e-19	0.476315859876846	0.0705352394789323	MirTarget;miRNATAP	-0.232289362179402	7.11654533343099e-05		NA	NA	NA
hsa-miR-106a-5p	PPP3CA	1.3902608059488	6.07931522284525e-05	-0.313973239016408	0.0165177462343014	miRNATAP	-0.133933104567234	1.19345709173472e-12		NA	NA	NA
hsa-miR-142-3p	PPP3CA	3.98476449801341	1.56256182021111e-35	-0.313973239016408	0.0165177462343014	miRNATAP	-0.118826172048727	2.75854825586705e-12		NA	NA	NA
hsa-miR-17-5p	PPP3CA	2.07078488653279	2.77403038572568e-19	-0.313973239016408	0.0165177462343014	miRNATAP	-0.176015588845375	7.62312188608765e-13		NA	NA	NA
hsa-miR-186-5p	PPP3CA	0.852175445703945	6.88885738584309e-10	-0.313973239016408	0.0165177462343014	mirMAP	-0.286847992743368	1.57472937315132e-11		NA	NA	NA
hsa-miR-20a-5p	PPP3CA	2.64649625616975	5.1469418982085e-27	-0.313973239016408	0.0165177462343014	miRNATAP	-0.154552998486965	9.11892644521842e-12		NA	NA	NA
hsa-miR-20b-5p	PPP3CA	1.35770573270947	0.00260808530013016	-0.313973239016408	0.0165177462343014	miRNATAP	-0.122294666346707	1.15249428256532e-19		NA	NA	NA
hsa-miR-30c-5p	PPP3CA	-0.327319105755825	0.123595832152687	-0.313973239016408	0.0165177462343014	miRNATAP	-0.10873673306536	0.000125286600086868		NA	NA	NA
hsa-miR-361-3p	PPP3CA	0.0988926195529967	0.549128728500555	-0.313973239016408	0.0165177462343014	MirTarget;PITA;miRNATAP	-0.173641727258806	2.07130127414673e-06		NA	NA	NA
hsa-miR-501-3p	PPP3CA	-0.0405952693028064	0.866802243505833	-0.313973239016408	0.0165177462343014	MirTarget;PITA;miRNATAP	-0.152231773192009	5.82453493976863e-10		NA	NA	NA
hsa-miR-502-3p	PPP3CA	-0.262270070977708	0.161760375279961	-0.313973239016408	0.0165177462343014	MirTarget;PITA;miRNATAP	-0.102225645893012	0.00155670003675052		NA	NA	NA
hsa-miR-589-3p	PPP3CA	1.34253876396688	1.84935927493927e-05	-0.313973239016408	0.0165177462343014	MirTarget	-0.111512777165905	9.25189699847489e-09		NA	NA	NA
hsa-miR-590-3p	PPP3CA	0.83851360565783	0.00129224433453587	-0.313973239016408	0.0165177462343014	miRanda;mirMAP	-0.108711400054004	7.97592745451833e-05		NA	NA	NA
hsa-miR-590-5p	PPP3CA	2.07441240363458	4.95240551694843e-14	-0.313973239016408	0.0165177462343014	PITA;miRanda;miRNATAP	-0.177690930412641	6.75602594094779e-12		NA	NA	NA
hsa-miR-7-1-3p	PPP3CA	2.61364240402652	1.98959237815786e-32	-0.313973239016408	0.0165177462343014	MirTarget;mirMAP	-0.121059394653456	5.88147588879243e-06		NA	NA	NA
hsa-miR-93-3p	PPP3CA	1.07631808403007	1.63747525692813e-05	-0.313973239016408	0.0165177462343014	miRNATAP	-0.170128744194282	3.50156314525736e-13		NA	NA	NA
hsa-miR-93-5p	PPP3CA	1.50844106515467	1.83836866996875e-12	-0.313973239016408	0.0165177462343014	miRNATAP	-0.25180151434334	1.28858993768457e-21		NA	NA	NA
hsa-miR-15a-5p	PPP3CB	1.62575353599172	1.55312121019827e-19	-0.217161149975175	0.026537796620393	miRNATAP	-0.123109224513088	2.45320870406106e-07		NA	NA	NA
hsa-miR-30c-5p	PPP3CB	-0.327319105755825	0.123595832152687	-0.217161149975175	0.026537796620393	miRNATAP	-0.117562918064524	1.93721091880072e-08		NA	NA	NA
hsa-miR-361-5p	PPP3CB	0.21454431962475	0.0800957579368424	-0.217161149975175	0.026537796620393	miRanda	-0.127974103120468	0.000592380004256261		NA	NA	NA
hsa-miR-361-5p	PPP3CC	0.21454431962475	0.0800957579368424	-0.864879436917075	5.11810186256782e-12	miRanda	-0.162282770575647	0.000912467378574366		NA	NA	NA
hsa-miR-181a-5p	PPP3R1	-0.375429731222937	0.0562142867129802	-0.021451907795778	0.828812244123992	MirTarget;miRNATAP	-0.174665544764319	9.40491398689482e-15		NA	NA	NA
hsa-miR-181b-5p	PPP3R1	0.668793269169928	0.000239998092406404	-0.021451907795778	0.828812244123992	MirTarget;miRNATAP	-0.114349020464675	3.84750784901666e-06		NA	NA	NA
hsa-miR-181c-5p	PPP3R1	0.529875814537156	0.0125885822998008	-0.021451907795778	0.828812244123992	MirTarget;miRNATAP	-0.106737924157465	4.8061231789594e-07		NA	NA	NA
hsa-miR-27b-3p	PPP3R1	0.236438984240408	0.12263510345883	-0.021451907795778	0.828812244123992	miRNATAP	-0.122284709618602	4.10399666262129e-05		NA	NA	NA
hsa-miR-30b-5p	PPP3R1	0.358144314839612	0.138026229059594	-0.021451907795778	0.828812244123992	MirTarget	-0.109418887183495	3.74739901258502e-09		NA	NA	NA
hsa-miR-30c-5p	PPP3R1	-0.327319105755825	0.123595832152687	-0.021451907795778	0.828812244123992	MirTarget;miRNATAP	-0.157231202749467	5.03548982239333e-14		NA	NA	NA
hsa-miR-342-3p	PPP3R1	-0.128691966564961	0.561034080130801	-0.021451907795778	0.828812244123992	MirTarget;miRanda;miRNATAP	-0.120856614371424	2.53668736670026e-09		NA	NA	NA
hsa-miR-34a-5p	PPP3R1	1.40588612517769	8.60097477768592e-12	-0.021451907795778	0.828812244123992	miRNAWalker2_validate	-0.170360603226023	4.36468130338985e-16		NA	NA	NA
hsa-miR-17-3p	PRKCA	1.36706429551147	4.60388403547821e-13	-0.189679589892687	0.471078192212991	miRNAWalker2_validate	-0.2211557176846	0.000413342702730225		NA	NA	NA
hsa-miR-181c-5p	PRKCA	0.529875814537156	0.0125885822998008	-0.189679589892687	0.471078192212991	mirMAP	-0.326745565499583	6.66432412436314e-09		NA	NA	NA
hsa-miR-183-5p	PRKCA	2.39247234736657	3.92444525331999e-21	-0.189679589892687	0.471078192212991	miRNATAP	-0.191021307259656	2.63755654536705e-05		NA	NA	NA
hsa-miR-193b-3p	PRKCA	1.10444771306846	0.000822888533401377	-0.189679589892687	0.471078192212991	miRNAWalker2_validate	-0.138487066621768	0.000138664149309437		NA	NA	NA
hsa-miR-193b-5p	PRKCA	0.179695858885499	0.55521472494233	-0.189679589892687	0.471078192212991	mirMAP	-0.137899397693864	0.000521039895191079		NA	NA	NA
hsa-miR-19b-1-5p	PRKCA	1.71217036351784	3.28561659177495e-12	-0.189679589892687	0.471078192212991	mirMAP	-0.210975845049586	0.000143708055393517		NA	NA	NA
hsa-miR-200c-3p	PRKCA	0.380533388300368	0.0842181838538353	-0.189679589892687	0.471078192212991	miRNATAP	-0.262911308228053	1.5097135867061e-06		NA	NA	NA
hsa-miR-22-5p	PRKCA	1.71436244278242	9.85038001236064e-15	-0.189679589892687	0.471078192212991	mirMAP	-0.177526746625668	0.000829577475678236		NA	NA	NA
hsa-miR-429	PRKCA	2.3794516574089	1.72813419703734e-13	-0.189679589892687	0.471078192212991	miRanda;miRNATAP	-0.142853746691809	0.000293353456114152		NA	NA	NA
hsa-miR-590-3p	PRKCA	0.83851360565783	0.00129224433453587	-0.189679589892687	0.471078192212991	PITA;miRanda;mirMAP;miRNATAP	-0.19448195031258	0.000455368438666445		NA	NA	NA
hsa-miR-92a-3p	PRKCA	-0.136362762339122	0.493412263619364	-0.189679589892687	0.471078192212991	miRNAWalker2_validate	-0.160805726714066	0.00861285946041943		NA	NA	NA
hsa-miR-93-3p	PRKCA	1.07631808403007	1.63747525692813e-05	-0.189679589892687	0.471078192212991	mirMAP	-0.159060267220526	0.000935006714973491		NA	NA	NA
hsa-miR-141-5p	PRKCB	3.02575703771074	1.54385222591327e-32	-1.01521651364956	0.000234705382361064	mirMAP	-0.19965194499171	1.76112086865619e-05		NA	NA	NA
hsa-miR-200b-3p	PRKCB	1.55157578247391	4.83790020897188e-09	-1.01521651364956	0.000234705382361064	MirTarget	-0.139521777238666	0.00328113460432514		NA	NA	NA
hsa-miR-200c-3p	PRKCB	0.380533388300368	0.0842181838538353	-1.01521651364956	0.000234705382361064	MirTarget;miRNATAP	-0.217004467533231	0.000183295321414174		NA	NA	NA
hsa-miR-335-3p	PRKCB	1.51116383169018	6.88553098788624e-13	-1.01521651364956	0.000234705382361064	mirMAP	-0.246405652657792	3.09182980578855e-05		NA	NA	NA
hsa-miR-429	PRKCB	2.3794516574089	1.72813419703734e-13	-1.01521651364956	0.000234705382361064	MirTarget;miRanda;miRNATAP	-0.166472060253132	6.28432741975052e-05		NA	NA	NA
hsa-miR-450b-5p	PRKCB	1.69248953402469	1.96052058003353e-07	-1.01521651364956	0.000234705382361064	miRNATAP	-0.183354145967975	2.13964194654069e-05		NA	NA	NA
hsa-miR-589-3p	PRKCB	1.34253876396688	1.84935927493927e-05	-1.01521651364956	0.000234705382361064	mirMAP	-0.153872579100374	0.000218865142512993		NA	NA	NA
hsa-miR-589-5p	PRKCB	0.233778899379261	0.228477190986199	-1.01521651364956	0.000234705382361064	mirMAP	-0.191889757915074	0.00377217964937973		NA	NA	NA
hsa-miR-590-5p	PRKCB	2.07441240363458	4.95240551694843e-14	-1.01521651364956	0.000234705382361064	miRanda	-0.247831270781318	8.78932489501914e-06		NA	NA	NA
hsa-miR-2110	PRKCG	-1.92124860612475	1.1464887721828e-12	1.66883505426905	0.000268885102920086	MirTarget	-0.307845409938279	6.49952836801256e-05		NA	NA	NA
hsa-miR-326	PRKCG	-0.992397386750901	0.00335173765975096	1.66883505426905	0.000268885102920086	miRanda	-0.268960075781158	1.49724165244188e-05		NA	NA	NA
hsa-miR-335-5p	PRKCG	-0.466533891325811	0.0676987038122831	1.66883505426905	0.000268885102920086	miRNAWalker2_validate	-0.28334410784476	0.00233636911178136		NA	NA	NA
hsa-miR-101-3p	PTGS2	1.38889039459232	1.96522549511542e-09	-1.03369714758802	0.032296876715107	miRNAWalker2_validate;miRTarBase;MirTarget;miRNATAP	-0.249551004902669	0.00850927718081984	24958470;26530100;21430074;24759835;26556718;24289600;23644120;26617722;19133256;24528073;25109742;23013439	Interestingly cyclooxygenase-2 inhibition by aspirin or celecoxib abrogated IL-1β-mediated repression of miR-101 and IL-1β-mediated activation of Lin28B along with their stimulatory effects on NSCLC cell proliferation and migration;Luciferase assay revealed that COX-2 was a direct target for miR-101-3p and overexpression of miR-101-3p decreased cellular COX-2 protein expression; Finally downregulation of miR-101-3p expression and upregulation of COX-2 was found in ESCC specimens from patients with smoking history; Taken together our findings revealed a new post-transcriptional mechanism by which CSE regulated COX-2 expression to favor cancer cell proliferation suggesting miR-101-3p as a potential biomarker and therapeutic target for smoke-related ESCC;Enforced expression of miR 101 inhibits prostate cancer cell growth by modulating the COX 2 pathway in vivo; In this study we investigated the mechanism of microRNA-101 miR-101-regulated COX-2 expression and the therapeutic potential of exogenous miR-101 for COX-2-associated cancer; We found that miR-101 inhibited COX-2 posttranscriptional expression by directly binding to the 3'-untranslated region 3'-UTR of COX-2 mRNA; In conclusion COX-2 is a direct target in miR-101 regulation of posttranscription; These data suggest that exogenous miR-101 may provide a new cancer therapy by directly inhibiting COX-2 expression;MiR-16 and miR-101 levels do not correlate with COX-2 mRNA and protein levels;Cyclooxygenase 2 a Potential Therapeutic Target Is Regulated by miR 101 in Esophageal Squamous Cell Carcinoma; This study investigated the effect of miR-101 on ESCC through modulating COX-2 expression in ESCC; The luciferase reporter assay was used to verify COX-2 as a direct target of miR-101; Furthermore COX-2 was shown to be a target of miR-101;The expression of COX-2 in Hela cell was also examined by immunohistochemical staining and the correlation with miR-101 expression was analysed; Thus reduced miR-101 expression could participate in the development of cervical cancer at least partly through loss of inhibition of target gene COX-2 which probably occurs in a relative late phase of carcinogenesis;Expressions of COX 2 PKC α and miR 101 in gastric cancer and their correlations; To investigate the expressions of miR-101 protein kinase C-α PKC-α and cyclooxygenase-2 COX-2 in gastric cancer GC tissue and their correlations; RT-qPCR was used to examine miR-101 expression and Western blotting employed to detect PKC-α and COX-2 expressions in 57 cases of gastric cancer tissues and paired normal gastric mucosal tissues; The gastric cancer tissues showed a significantly lower miR-101 expression Z=6.102 P<0.05 but significantly higher expressions of COX-2 Z=14.436 P<0.05 and PKC-α Z=6.955 P<0.05 than the normal gastric tissues; PKC-α expression was positively correlated r=0.531 P<0.05 and miR-101 expression negatively correlated r=-0.627 P<0.05 with COX-2 expression in gastric cancer tissues; miR-101 PKC-α and COX-2 all play a role in the tumorigenesis and progression of gastric cancer; miR-101 and PKC-α might be new potential therapeutic targets for inhibiting COX-2 in gastric cancer;Immunohistochemistry was performed to assess protein expression of the miR-101 target gene COX-2; Overexpression of miR-101 decreased expression of its target gene Cox-2 and inhibited proliferation and invasion and promoted apoptosis to suppress tumorigenicity;MiR 101 downregulation is involved in cyclooxygenase 2 overexpression in human colon cancer cells; In this paper we report the inverse correlation between COX-2 and miR-101 expression in colon cancer cell lines and we demonstrated in vitro the direct inhibition of COX-2 mRNA translation mediated by miR-101; These findings provide a novel molecular insight in the modulation of COX-2 at post-transcriptional level by miR-101 and strengthen the observation that miRNAs are highly implicated in the control of gene expression; An impairment of miR-101 levels could represent one of the leading causes of COX-2 overexpression in colon cancer cells;Roles of MiR 101 and its target gene Cox 2 in early diagnosis of cervical cancer in Uygur women; Use of down-regulation of miR-101 and up-regulation of Cox-2 as markers may play a role in early diagnosis of cervical cancer in Uygur women;Enforced expression of miR 101 enhances cisplatin sensitivity in human bladder cancer cells by modulating the cyclooxygenase 2 pathway;Downregulation of miR 101 in gastric cancer correlates with cyclooxygenase 2 overexpression and tumor growth; Here we characterize miR-101 expression and its role in the regulation of COX-2 expression which in turn will provide us with additional insights into the potential therapeutic benefits of exogenous miR-101 for treatment of gastric cancer; We also found an inverse correlation between miR-101 and COX-2 expression in both gastric cancer specimens and cell lines; One possible mechanism of interaction is that miR-101 inhibited COX-2 expression by directly binding to the 3'-UTR of COX-2 mRNA; These results collectively indicate that miR-101 may function as a tumor suppressor in gastric cancer with COX-2 as a direct target	;;;;;tumorigenesis;progression;tumorigenesis;;;;;	lung cancer;esophageal cancer;prostate cancer;liver cancer;esophageal cancer;cervical and endocervical cancer;gastric cancer;cervical and endocervical cancer;colon cancer;cervical and endocervical cancer;bladder cancer;gastric cancer
hsa-miR-146b-5p	PTGS2	1.0922867893808	5.63754607494775e-06	-1.03369714758802	0.032296876715107	miRanda	-0.370951337285379	5.00511906316448e-05		NA	NA	NA
hsa-miR-16-2-3p	PTGS2	0.503964803530872	0.0263648405197492	-1.03369714758802	0.032296876715107	mirMAP	-0.334544410725452	0.00170989664243796		NA	NA	NA
hsa-miR-16-5p	PTGS2	0.749619098384047	4.11649450706988e-06	-1.03369714758802	0.032296876715107	miRNAWalker2_validate;miRTarBase	-0.557741889577594	4.18248826425404e-05	24759835;25196524	MiR-16 and miR-101 levels do not correlate with COX-2 mRNA and protein levels;Artesunate induces apoptosis of bladder cancer cells by miR 16 regulation of COX 2 expression; Cyclooxygenase-2 COX-2 and miR-16 expression levels were determined with real-time PCR; ART efficiently inhibited orthotopic tumor growth in the bladder cancer rat which is accompanied with an increase of miR-16 expression and a decrease of COX-2 expression; ART significantly increased miR-16 expression and decreased the expression of COX-2 and the production of PGE2; More importantly down-regulation of miR-16 expression could reverse the effect of ART on apoptosis and COX-2 expression in bladder cells; In conclusion ART can elicit an anti-tumor effect against bladder cancer by up-regulation of miR-16 expression which resulted in the decrease of COX-2 expression and PGE2 production	;	liver cancer;bladder cancer
hsa-miR-17-5p	PTGS2	2.07078488653279	2.77403038572568e-19	-1.03369714758802	0.032296876715107	miRNAWalker2_validate	-0.263976599489779	0.004496619277825		NA	NA	NA
hsa-miR-29b-1-5p	PTGS2	1.71024742617744	3.64915691793611e-09	-1.03369714758802	0.032296876715107	MirTarget	-0.296673951688718	8.05914160567646e-05		NA	NA	NA
hsa-miR-362-3p	PTGS2	0.194097672030785	0.52808475179225	-1.03369714758802	0.032296876715107	miRanda	-0.247201801855878	0.00642369816175574		NA	NA	NA
hsa-miR-7-1-3p	PTGS2	2.61364240402652	1.98959237815786e-32	-1.03369714758802	0.032296876715107	MirTarget	-0.32165354375189	0.00120377123008504		NA	NA	NA
hsa-miR-140-5p	PTK2	0.669142684153918	0.000335928403032308	0.278007300053823	0.026596373778384	miRanda	-0.161505490487641	2.71491649672642e-07		NA	NA	NA
hsa-miR-335-5p	PXN	-0.466533891325811	0.0676987038122831	-0.370846857620499	0.00947181315964173	miRNAWalker2_validate	-0.100714810055646	0.000474599225786488		NA	NA	NA
hsa-miR-30c-5p	RAC1	-0.327319105755825	0.123595832152687	0.217355195910818	0.0528286499053578	miRNAWalker2_validate	-0.11419324793125	2.23761362474291e-06		NA	NA	NA
hsa-miR-193b-3p	RAC2	1.10444771306846	0.000822888533401377	-0.656275624483639	0.00297441142612925	miRNAWalker2_validate	-0.112838589622127	0.000231783502607722		NA	NA	NA
hsa-miR-125a-5p	RAC3	-1.04824536696301	3.97386082850476e-07	1.82835649257478	3.33704760151114e-09	PITA	-0.183541043002533	0.00831332585841968		NA	NA	NA
hsa-miR-30c-2-3p	RAC3	-3.10905250533941	6.84550165664783e-27	1.82835649257478	3.33704760151114e-09	miRNAWalker2_validate	-0.370936437115312	5.24524075378395e-16		NA	NA	NA
hsa-miR-330-3p	SPHK1	-0.716924999893351	0.000796236278616087	0.49292057318817	0.0966832552880382	miRNATAP	-0.269842391482062	2.17580041220939e-05		NA	NA	NA
hsa-miR-195-5p	SRC	-1.01577502605386	4.80814718341729e-05	0.536847781930278	0.000183762865185033	mirMAP	-0.129046385477166	3.02317610630897e-06		NA	NA	NA
hsa-miR-1-3p	VEGFA	-1.48412019995919	0.000242034342580425	0.230749341603949	0.311300638391058	MirTarget	-0.172921089301484	3.76698090411866e-10	24966896	The ectopic expression of miR-1 and miR-145 in NOZ cells significantly inhibited cell viability and colony formation P<0.01 and reduced gene expression of VEGF-A and AXL		bladder cancer
hsa-miR-101-3p	VEGFA	1.38889039459232	1.96522549511542e-09	0.230749341603949	0.311300638391058	miRNAWalker2_validate	-0.184546125824104	3.21659312920503e-05		NA	NA	NA
hsa-miR-125a-3p	VEGFA	-1.04954492275266	2.45974219476832e-06	0.230749341603949	0.311300638391058	miRanda	-0.155505773345232	0.000854677712414177	22768249	Ectopic expression of MiR 125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF; Furthermore miR-125a expression was inversely correlated with both MMP11 and VEGF-A expression in HCC tissues; MiR-125a inhibits the proliferation and metastasis of HCC by targeting MMP11 and VEGF-A	metastasis	liver cancer
hsa-miR-133a-3p	VEGFA	-2.89609207852024	1.71222048144972e-13	0.230749341603949	0.311300638391058	miRNAWalker2_validate	-0.104720990536239	5.4001689907379e-05		NA	NA	NA
hsa-miR-140-5p	VEGFA	0.669142684153918	0.000335928403032308	0.230749341603949	0.311300638391058	miRNAWalker2_validate;miRTarBase;MirTarget;miRanda;miRNATAP	-0.246162039129829	1.79001025551982e-05	26402430	MicroRNA 140 5p inhibits the progression of colorectal cancer by targeting VEGFA; The direct regulation of VEGFA by miR-140-5p was identified using luciferase reporter assay; Integrated analysis identified VEGFA as a direct and functional target gene of miR-140-5p; Silencing VEGFA by small interfering RNA siRNA resembled the phenotype resulting from ectopic miR-140-5p expression while overexpression of VEGFA attenuated the effect of miR-140-5p on CRC cells; Our results suggested a tumor suppressive role of miR-140-5p in CRC tumorigenesis and progression by targeting VEGFA	progression;tumorigenesis	colorectal cancer
hsa-miR-150-5p	VEGFA	-0.702328520623782	0.0215316651134431	0.230749341603949	0.311300638391058	miRNAWalker2_validate;miRTarBase	-0.211938415847961	3.12072029375035e-10		NA	NA	NA
hsa-miR-195-5p	VEGFA	-1.01577502605386	4.80814718341729e-05	0.230749341603949	0.311300638391058	miRNAWalker2_validate;miRTarBase;MirTarget	-0.216253591570711	7.05557590450539e-07	27574422;23468064;26823724	In this study we used a new cationic peptide disulfide cross-linked stearylated polyarginine peptide modified with histidine H3R5 as a reducible vector cell penetrating peptide-modified aptamer ST21 with specific binding to HCC cells to conjugate to peptide H3R5 as the targeting probe miRNA-195 miR195 as a powerful gene drug to inhibit VEGF and fasudil to suppress vasculogenic mimicry by blocking ROCK2 all of which were simultaneously encapsulated in the same nanoparticles;Furthermore we revealed that miR-195 down-regulation resulted in enhanced VEGF levels in the tumor microenvironment which subsequently activated VEGF receptor 2 signaling in endothelial cells and thereby promoted angiogenesis;MiR 195 is a key negative regulator of hepatocellular carcinoma metastasis by targeting FGF2 and VEGFA; Luciferase reporter and ELISA assay prove that hematogenous metastasis related genes including FGF2 and VEGFA are the target genes of miR-195; Taken together our results suggest that miR-195 a tumor suppressor miRNA contributes to the lung metastasis of HCC by negatively regulating FGF2 and VEGFA providing key implications of miR-195 for the therapeutic intervention of HCC	;;metastasis	liver cancer;liver cancer;liver cancer
hsa-miR-29c-3p	VEGFA	1.32354490728858	1.84279305179762e-07	0.230749341603949	0.311300638391058	miRNAWalker2_validate;MirTarget	-0.189793475587463	2.81724907347383e-06		NA	NA	NA
hsa-miR-330-3p	VEGFA	-0.716924999893351	0.000796236278616087	0.230749341603949	0.311300638391058	miRNAWalker2_validate	-0.385541553437526	4.9599607016426e-16		NA	NA	NA
hsa-miR-335-5p	VEGFA	-0.466533891325811	0.0676987038122831	0.230749341603949	0.311300638391058	miRNAWalker2_validate	-0.139733266743143	0.00237085343344445		NA	NA	NA
hsa-miR-361-5p	VEGFA	0.21454431962475	0.0800957579368424	0.230749341603949	0.311300638391058	miRNAWalker2_validate;miRTarBase;MirTarget;miRanda;miRNATAP	-0.311546652005902	0.000341919545726308		NA	NA	NA
hsa-miR-374a-3p	VEGFA	1.73882813668241	1.57901646296214e-13	0.230749341603949	0.311300638391058	MirTarget	-0.116308302225143	0.0073756212717737	23679262	Our data demonstrated miR-374a to be differentially distributed in breast cancer; VEGF-A and VCAM-1 mRNA had coincident distribution and the distribution of teh respective proteins was uneven and opposite to that for the miR-374a		breast cancer
hsa-miR-374a-5p	VEGFA	-0.197027254874826	0.298080902192861	0.230749341603949	0.311300638391058	MirTarget	-0.195164100931073	0.0017653451750918	23679262	Our data demonstrated miR-374a to be differentially distributed in breast cancer; VEGF-A and VCAM-1 mRNA had coincident distribution and the distribution of teh respective proteins was uneven and opposite to that for the miR-374a		breast cancer
hsa-miR-374b-5p	VEGFA	0.474691035780475	0.0109217471394203	0.230749341603949	0.311300638391058	MirTarget	-0.165654325982956	0.00541935782229369		NA	NA	NA
hsa-miR-378a-3p	VEGFA	-2.0140903990983	1.146745431034e-18	0.230749341603949	0.311300638391058	miRNAWalker2_validate;miRTarBase	-0.188122556602091	1.9053920640873e-05		NA	NA	NA